Nature Communications (Dec 2017)
Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma
- Elisa Lazzari,
- Phoebe K. Mondala,
- Nathaniel Delos Santos,
- Amber C. Miller,
- Gabriel Pineda,
- Qingfei Jiang,
- Heather Leu,
- Shawn A. Ali,
- Anusha-Preethi Ganesan,
- Christina N. Wu,
- Caitlin Costello,
- Mark Minden,
- Raffaella Chiaramonte,
- A. Keith Stewart,
- Leslie A. Crews,
- Catriona H. M. Jamieson
Affiliations
- Elisa Lazzari
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Phoebe K. Mondala
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Nathaniel Delos Santos
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Amber C. Miller
- Department of Medicine, Mayo Clinic
- Gabriel Pineda
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Qingfei Jiang
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Heather Leu
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Shawn A. Ali
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Anusha-Preethi Ganesan
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Christina N. Wu
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Caitlin Costello
- Department of Medicine, Moores Cancer Center at University of California, San Diego
- Mark Minden
- Princess Margaret Hospital, University Health Network
- Raffaella Chiaramonte
- Department of Health Sciences, University of Milan
- A. Keith Stewart
- Department of Medicine, Mayo Clinic
- Leslie A. Crews
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- Catriona H. M. Jamieson
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego
- DOI
- https://doi.org/10.1038/s41467-017-01890-w
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 10
Abstract
The treatment of multiple myeloma is challenging due to high relapse rates. Here the authors show that expression of ADAR1 correlates with poor patient outcomes, and that ADAR1-mediated editing of GLI1 is a mechanism relevant in the context of multiple myeloma progression and drug resistance.
